Health

First Ebola vaccine approved for use in Europe in move which could save thousands of lives


THOUSANDS of lives could be saved after the first Ebola vaccine was approved for use in Europe.

US drugmaker Merck & Co received consent to market the booster, known as Ervebo, from the European Commission on Monday.

 US pharmaceutical maker Merck & Co has received approval from the European Commission to market its Ebola vaccine

2

US pharmaceutical maker Merck & Co has received approval from the European Commission to market its Ebola vaccineCredit: Reuters

The drug is already being used under emergency guidelines to try to protect against the spread of the deadly virus in Democratic Republic of Congo.

The Ebola vaccine, which is approved for individuals aged 18 or over, was authorised less than a month after the European Medicines Agency recommended it be licensed.

EU Ebola Coordinator Christos Stylianides said: “The EU is supporting international efforts to combat Ebola on all fronts, from vaccine development to delivering humanitarian aid on the ground.”

Dr Charlie Weller, Wellcome’s Head of Vaccines added: “It’s been a long journey and made possibly a truly global collaborative effort of researchers, governments, NGOs, companies and funders.

Best possible care

“Wellcome is very proud to have been among those who have played a part.

“We commend Merck for their commitment to developing this vaccine.

“But we should all pay tribute to the brave healthcare workers who have provided the best possible care in conducting the trials, as well as the leadership in the DRC, for this vital research.”

The current outbreak is largely confined to Congo – and due to its scale the UN health agency declared it an international emergency in July.

Deadly outbreak

It marks the second-deadliest Ebola outbreak in history.

To date, there have been 3,113 confirmed cases and more than 2,150 people have died since the outbreak of the epidemic.





READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.